Healthcare REIT LTC Q3 revenue beats expectations, helped by SHOP expansion

Reuters
2025/11/05
Healthcare REIT LTC Q3 revenue beats expectations, helped by SHOP expansion 

Overview

  • LTC Q3 2025 revenue grows significantly, beating analyst expectations

  • Company reports Q3 net loss due to non-cash write-offs and increased expenses

  • LTC raises full-year guidance, driven by acquisitions and SHOP outperformance

Outlook

  • Company raises full-year 2025 EPS guidance to $2.45-$2.47

  • LTC expects Q4 2025 Core FFO per share of $0.67-$0.69

  • Company anticipates closing $70 mln in SHOP acquisitions by year-end

Result Drivers

  • SHOP EXPANSION - Co attributes revenue growth to conversions of triple-net lease portfolios into SHOP and new SHOP acquisitions

  • ASSET SALES - Proceeds from selling older skilled nursing centers redeployed for newer SHOP assets

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$69.29 mln

$33.19 mln (3 Analysts)

Q3 EPS

-$0.44

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the specialized reits peer group is "buy."

  • Wall Street's median 12-month price target for LTC Properties Inc is $37.00, about 4.4% above its November 3 closing price of $35.39

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nBw5h9LFKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10